

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 02-006; A-415H)

PATENT

In re Application of: Fisher et al.)
Serial No.: 09/882,735) Before the Examiner: E. O'Hara
Filed: June 15, 2001) Group Art Unit: 1646
For: Truncated Soluble Tumor Necrosis Factor Type-I and Type-II Receptors)))
Commissioner for Patents	

P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

- 1. We are transmitting herewith the attached papers for the above-described patent application:

 Petition for Extension of Time, Response to Office Action, paper and computer-readable copies of Sequence Listing, Statement under 37 C.F.R. § 1.821(f), Change of Correspondence Address, Associate Power of Attorney, and return postcard.
- 2. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.
- 3. CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 21, 2003.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: August 21, 2003

Donald L. Zuhn, Pa.D.

Reg. No. 48,710

AUG 2 5 2003 P. S. S. TRADEMAN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 02-006; A-415H)

PATENT

Th re Application of:	Fisher et al.)
		1

Serial No.: 09/882,735

Before the Examiner: E. O'Hara

Filed: June 15, 2001)

Group Art Unit: 1646

For: Truncated Soluble Tumor Necrosis

Factor Type-I and Type-II Receptors)

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 C.F.R. § 1.821(f)

The undersigned representative hereby declares that the content of the paper and computer readable copies of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are identical, and further, that the submission of the paper and computer readable copies of the Sequence Listing adds no new matter. The 3.5" diskette contains an IBM compatible dos-text file of the sequence listing named "02006Aseq.txt." Consideration and entry of this Statement and attachments are respectfully requested.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: August 21, 2003

By: Donald Zuhn, l

Reg. No. 48,71

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington P.C. 20231, on August 21, 2003.

Donald L. Zuhn



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 02-006; A-415H)

PATENT

In re Application of: Fisher et al.)
Serial No.: 09/882,735	Before the Examiner: E. O'Hara
Filed: June 15, 2001) Group Art Unit: 1646
For: Truncated Soluble Tumor Necrosis Factor Type-I and Type-II Receptors))

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE TO OFFICE ACTION MAILED FEBRUARY 21, 2003

Responsive to the Office Action mailed February 21, 2003, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

AMENDMENTS

The Examiner is respectfully requested to enter the following amendments. Pursuant to revised 37 C.F.R. § 1.121, Applicants present the amendments to the specification at page 2, marked up to show changes made relative to the immediate prior version of the specification, and a complete listing of the claims, including marked up versions of all currently amended claims, at pages 3-10.

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington D.C. 20231, on August 21, 2003